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Viridans group streptococci: a reservoir of resistant bacteria
in oral cavities
A. Bryskier
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The worldwide spread of erythromycin A-resistant streptococci, including Streptococcus
pneumoniae, is of concern. Many studies have demonstrated that the viridans group
streptococci can be a reservoir of erythromycin A resistance. Within oral streptoccoci, an
important difference in the susceptibility pattern has been noted. The purpose of this
short editorial is to highlight the importance of this group of bacteria as a reservoir of
resistance to erythromycin A and the possible transfer of resistance to S. pneumoniae and
S. pyogenes.
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The nasooropharynx is the ﬁrst line of defense
against infections. The microﬂora is part of the
host defense system which is established during
the ﬁrst week of life. In the nasal cavities, the
bacterial ﬂora is mainly composed of coryneforms
and coagulase-negative staphylococci, but in the
oropharynx the dominant bacterial inhabitants are
the oral streptococci. The different species of oral
streptococci are not distributed uniformly in these
cavities.
Currently, at least 18 species are recognized,
since the taxonomy of viridans group streptococci
has undergone considerable revision in recent
years. Themitis group contains the largest number
of named species of oral streptococci. The species
or group species comprising these streptococci are
S. salivarius, S. mutans, the Anginosus group (S.
anginosus, S. constellatus and S. intermedius), S.
sanguis and the S. mitis group [1]. Data from rRNA
show that S. pneumoniae belongs to the mitis group
of oral streptococci. Though the main S. pneumo-
niae habitat is considered to be the nasopharynx
rather than the oral cavity, S. pneumoniae is closely
related to S. oralis and S. mitis, and there is enough
evidence to show that there is extensive exchange
of genetic information between these species [2].
The oral streptococci are normal commensals of
the human mouth and play a role in resistance to
colonization by other bacterial species such as
staphylococci. Colonization is inhibited by hydro-
gen peroxide production by some oral streptococ-
cal species. However, it offers a pool of genetic
material which can undergo gene shufﬂing with
other bacteria, including pathogenic species, and
lead to the emergence of resistant strains [3]. Inter-
est has been renewed in these species due to the
emergence and spread of bacterial resistance
within respiratory microorganisms to penicillin
G and erythromycin A and also the possibility
of transferring genetic material from oral strepto-
cocci to S. pneumoniae or S. pyogenes. Antibiotic
resistance within these oral streptococcal species
may act as a reservoir of resistance. As viridans
group streptococci form part of the normal ﬂora, it
is hypothesized that the presence of a resident
microﬂora in the throat is important to protect
against the invasive capacity of S. pyogenes [4,5].
In vitro and in vivo studies have demonstrated
that the viridans group streptococci inhabiting the
oropharynx suppress the growth of Gram-positive
cocci and bacilli but are not responsible for growth
control of Gram-negative bacteria in vivo.
It has also been shown that there is heterogene-
ity in antibiotic susceptibility among species in the
group, especially for penicillin G and erythromy-
cin A and derivatives [6].
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It has been demonstrated that uptake of DNA
from related bacterial species present in the same
ecologic niche, such as S. mitis, S. oralis and S.
gordonii, followed by recombination into the chro-
mosome, can provide S. pneumoniae with ‘new
genes’. Mosaic pbp genes found in clinical isolates
of S. pneumoniae resistant to penicillin G are an
example of replacement of parts of susceptible
genes by sequences from related species. S. oralis
and S. mitis are likely donors of some of the
sequences [7,8]. Another example, the transforma-
tion of S. pneumoniae isolates from optochin sus-
ceptible to optochin resistant, has been observed
using S. oralis chromosomal DNA as donor [9].
In vitro transfer of ﬂuoroquinolone determinants
from viridans group streptococci to S. pneumoniae
has also been demonstrated [10].
Viridans group streptococci are mainly in-
volved in endocarditis or infection in neutropenic
patients. As was shown in a recent survey in the
the UK [11], 86% of the 607 clinical isolates from
endocarditis patients were viridans group strep-
tococci, and four main species accounted for over
two-thirds of the isolates. Some 15% of S. oralis,
14.5% of S. sanguis and 5.5% of S. gordonii isolates
had reduced susceptibility to penicillin G, whereas
all S. bovis type 1 and S. mutans isolates were
susceptible to penicillin G and erythromycin A.
There have been few epidemiologic surveys in
patients.
In the Netherlands, in a recent study carried out
from September 1995 to June 1999, 342 isolates
were recovered and only 11 (3.2%) were consid-
ered to be resistant to erythromycin A, which was
regarded as a moderate increase in comparison
with a previous period in the same hospital, when
2.6% of the isolates were resistant to erythromycin
A [12,13]. Comparable data were reported from
Argentina in 1996 [14]. A higher resistance rate
had been reported from Spain, with 14.3% and
17.7% of erythromycin A resistance in 1994 and
1999, respectively [15,16]. In France, the incidence
rate of erythromycin A within the viridans group
streptococci was about 40% between 1988 and 1995
[17].
In the study from the Netherlands, the presence
of erm(B), erm(TR) and mef(A) genes was demon-
strated. The erm(B)-containing isolates were domi-
nant, accounting for 68.2% of the isolates; this
was also found in another study [18]. The erm(TR)
gene-containing isolates are uncommon, and are
only reported in one study [13] from two isolates of
S. anginosus. In Japan, isolates containing erm(B)
and mef(E) were equally represented in a 1999
study [19].
The variation in antibacterial resistance within
the different viridans group streptococcal species
has been demonstrated in a study from the UK [11]
and in another from Taiwan [20].
In the Taiwan study, a bimodal distribution of
erythromycin A susceptibility has been shown in
the anginosus group of streptococci, in S. mitis
and in S. salivarius, with erythromycin A MIC50
and MIC90 values of 0.06mg/L and >64mg/L,
respectively. S. mitiswas themost resistant species,
with only 50% of the isolates being susceptible
to erythromycin A (MIC50 0.25mg/L, MIC90
512mg/L); S. oralis isolateswere poorly susceptible
to erythromycin A (only 45% were susceptible),
with erythromycinAMIC50 andMIC90 values of 4.0
and 512mg/L, respectively, followed by S. san-
guis (47% susceptible), with erythromycin AMIC50
and MIC90 values of 2.0 and 512mg/L, respec-
tively. The species most susceptible to erythromy-
cin A was S. mutans (100%), with erythromycin A
MIC50 and MIC90 values of <0.03 and 0.25mg/L,
respectively. In this study, there was a high inci-
dence of penicillin G and tetracycline resistance
combined with resistance to erythromycin A.
This fact was also demonstrated by other studies
[21].
In 1996, 56% of viridans streptococci isolates
were resistant to penicillin G in the USA. This
antibacterial agent had exhibited good antistrep-
tococcal activity 20 years ago [22,23]. In Canada,
of 418 viridans streptococcal strains isolated from
blood culture between May 1995 and March 1997,
28%, 12%, 40%, 4%, 24% and 34% were interme-
diately susceptible or resistant to penicillin G,
amoxicillin, ceftriaxone, erythromycin A, clinda-
mycin, tetracycline, and co-trimoxazole, respec-
tively. Two hundred and thirty-six isolates were
resistant to at least one or more antibacterials.
Within the 236 strains, 125, 56, 17 and 13 were
S. mitis, S. sanguis, S. salivarius, and non-typable,
respectively. For an erythromycin A MIC¼
0.5mg/L, 53%, 32%, 41% and 62% of these isolates
were resistant to erythromycinA, respectively [24].
During 1999, 198 pharyngeal exudates obtained
from outpatients in Madrid were studied. A con-
trol group of 50 healthy persons (adults and chil-
dren) who had not received antibiotic treatment
in the previous 3months were collected. Of the
viridans group streptococci, 60.8% were resistant
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to erythromycin A or azithromycin, due to an
mef(A) gene (MICs ranged from 2 to 4mg/L),
and 15.6% were resistant to erythromycin A,
due to an MLSB mechanism of resistance. In
healthy persons, 50.7% of the viridans group strep-
tococci isolates were resistant to erythromycin A,
harboring an mef(A) gene, and 12.7% harbored an
erm gene. No detail at the species level has been
reported [25].
Since the ﬁrst report of decreased erythromycin
susceptibility, in 1959, in S. pyogenes [26], erythro-
mycin A resistance has spread worldwide. The
same pattern occurred with S. pneumoniae, with
an increased incidence rate of resistance to ery-
thromycin A and with full cross-resistance
between erythromycin A, clarithromycin and azi-
thromycin.
Many studies have investigated the relationship
between antibacterial treatment of a patient and
that patient’s risk of carrying or being colonized or
infected by a penicillin G- and/or erythromycin A-
resistant strain. However, the data collected have
varied considerably from one study to another.
The variation reﬂects differences in study design,
the time scale and the setting, as well as the
measure of association used [27].
Several reports have highlighted the fact that the
administration of various antibiotics may lead to
an increased number of resistant streptococci
within the oral cavity.
Inmany studies, it was shown that, immediately
after the ﬁrst administration of erythromycin base
or 20-esters or salt (stearate) [28,29], josamycin,
roxithromycin [30], or clarithromycin, there is a
decrease in the population of viridans streptococci.
All of these studies showed that the majority of
people carry various levels of erythromycin A-
resistant streptococci in their oral cavity before
administration of the antibiotics. However, the
method used to isolate these strains could be
responsible for the variation in isolation rates
among erythromycin A-resistant strains. For
instance, addition of pyridoxal [31] increases the
rate of isolation of streptococci resistant to erythro-
mycin A. MICs of erythromycin A have ranged
from 0.25 to >64mg/L.
The proportion of erythromycin A-resistant
streptococci in volunteers had declined substanti-
ally after 1 week and then continued to decline for
up to 3 months, although still remaining at slightly
higher levels than before the course of erythro-
mycin treatment. In one study, erythromycin
A-resistant streptococci were found to persist for
up to 43weeks in some subjects [32]. The ecological
effect on the oral commensal ﬂora during admin-
istration of telithromycin and clarithromycin has
also been investigated in healthy volunteers. In the
oropharyngeal microﬂora, the viridans strepto-
cocci population decreased signiﬁcantly with both
compounds, but telithromycin MICs remained
low (MICs ranged from 0.016 to 1.0mg/L) [33].
The resistance proﬁles of some species of vir-
idans group streptococci can represent a good
marker for the risk of emergence of resistance to
erythromycin A in a given bacterial population of
S. pyogenes or S. pneumoniae. The transfer by con-
jugation of erythromycin A resistance from viri-
dans group streptococci to S. pneumoniae, and vice
versa, have been demonstrated [34], as well as
from strains of S. pyogenes to S. pyogenes BMI37
and Enterococcus faecalis [35].
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